Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Harmony Biosciences, LLC	72028004503	WAKIX™ (pitolisant) 4.45 MG  30 Tablets	2019-10-01	2842.5000	None	1	None	1	1	None	None	None	None	Harmony does not have patented marketing information. Any marketing information related to this product is know only to Harmony’s Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Harmony to obtain a business advantage over its competitors who do not have or know Harmony’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. Harmony does not have an estimate of the number of patients, and therefore, we cannot provide this information. Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States.	None
Harmony Biosciences, LLC	72028017803	WAKIX™ (pitolisant) 17.8 MG 30 Tablets	2019-10-01	5685.0000	None	1	None	1	1	None	None	None	None	Harmony does not have patented marketing information. Any marketing information related to this product is know only to Harmony’s Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Harmony to obtain a business advantage over its competitors who do not have or know Harmony’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. Harmony does not have an estimate of the number of patients, and therefore, we cannot provide this information. Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States.	None